Gut Microbiome May Play an Important Role in Immunotherapy in the Future, But More Research is Needed

Video

The microorganisms inside a patient's gastrointestinal tract may have a role to play in how immunotherapy can treat certain types of cancer.

The microorganisms and other genetic material present in the gastrointestinal tract — also known as the gut microbiome – could play an important role in the treatment of certain types of cancers, according to Dr. Jason Luke.

In an interview with CURE®’s sister publication, OncLive®, Luke, the director of the Cancer Immunotherapeutics Center at UPMC and the University of Pittsburgh, explained that while scientists are just now beginning to understand the impact of the microbiome when it comes to certain types of immune responses seen in some patients, more research is needed to determine how to use this information in future treatment plans.

Transcription:

One of the most interesting areas of research, I think, in oncology over the last few years has been the identification that the contents of the gut or the fecal microbiome can really (have an) impact on the outcomes of patients, especially with immunotherapy to cancer. We're only just beginning to understand this in any meaningful way, but several groups now have reported that certain kinds of bacteria being more present makes it more likely for the immune response to kick in and fight the cancer.

So, the question then becomes, is that a biomarker? Or is that something that we could modulate as if it's like a drug? And those are open questions. There are clinical trials ongoing to try to address this. On a practical level, however, patients really dig this. And they always ask about it. So, what can we do right now?

I think what we can say right now is that we don't know the answer. And we should not be recommending to patients that they take probiotics, because in fact, there's some evidence that actually suggests that probiotics might be worse.

More generally, what we do know is that just like everything else, three meals a day that are heavy on fiber and green vegetables are good for immunotherapy also. So simple stuff is the way to go right now, but this is definitely a space that's evolving and pretty exciting when we think about the future in terms of treatment.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE